Literature DB >> 23758761

Validation of SYBR Green based quantification assay for the detection of human Torque Teno virus titers from plasma.

Anuj Kumar Tyagi1, Amandine Pradier, Odile Baumer, Chakradhara Rao S Uppugunduri, Patricia Huezo-Diaz, Klara M Posfay-Barbe, Eddy Roosnek, Marc Ansari.   

Abstract

BACKGROUND: Quantification of titers of ubiquitous viruses such as Torque teno virus (TTV) that do not cause clinical symptoms might be helpful in assessing the immune status of an individual. We hereby describe the validation of a SYBR Green-based TTV quantification method for plasma samples.
METHODS: Plasmids with TTV specific inserts were used for preparing standards and absolute quantification of TTV was performed using SYBR Green methodology. The method was assessed for its accuracy and precision (intra and inter-day) on four non-consecutive days. TTV was also quantified from plasma samples of 20 healthy volunteers and from 30 hematopoietic stem cell transplant (HSCT) recipients.
RESULTS: The assay was specific and showed satisfactory efficiency (82.2%, R2=0.99) with the limit of quantification defined as 100 copies per reaction. The assay had good precision (inter and intra-day coefficient of variation in cycle threshold (CT) < 4%) and accuracy (100 ± 10%) in the range of 100 to 1010 copies/reaction. We found TTV loads ranging from 2.5 - 4.07 log copies/mL of plasma with CT (mean ± SD) of 33.8 ± 1.77 in healthy individuals and 2.06 - 8.49 log copies/mL of plasma with CT (mean ± SD) of 24.3 ± 1.04 in HSCT recipients.
CONCLUSION: SYBR Green-based q-PCR assay combines simplicity with satisfactory sensitivity and may be suitable for monitoring the immune status of transplant recipients, where TTV loads over time may serve as a marker for immune reconstitution in human plasma samples.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23758761      PMCID: PMC3698114          DOI: 10.1186/1743-422X-10-191

Source DB:  PubMed          Journal:  Virol J        ISSN: 1743-422X            Impact factor:   4.099


Background

Torque teno virus (TTV), classified into the family anelloviridae, genus alphatorquevirus, was first described in a patient with non-A-E hepatitis [1,2]. TTV is a non-enveloped, single-stranded, circular DNA virus present in plasma of >90% of individuals, regardless of geographical origin, age or health status [2,3]. Viral titers in the plasma may reflect the individual’s immune status, since immunocompromised patients harbor high loads of TTV [4]. This approach can be used to estimate immune recovery in hematopoietic stem cell transplant (HSCT) recipients by monitoring TTV titers after transplantation [5]. TTV DNA has a total genomic length of approximately 3.8 kilobases [6-9] and contains two large-open reading frames (ORF1 and ORF2) and several smaller ORFs [3]. TTV exhibits a wide range of sequence variability, with at least 38 TTV genotypes and forms five distinct phylogenetic groups [10-13]. The conserved ORF-2 region allows the design of primers expected to amplify most strains of TTV [14]. Several previously described quantification methods for human TTV [15-17] are based on TaqMan technology, which may be less suitable for quantification of highly variable viruses such as TTV. SYBR Green-based PCR with primers annealing to more conserved regions may be preferable. In the present study, we report the validation of SYBR Green based quantification assay for routine use by using a set of primer pairs targeted for amplifying a well-conserved sequence of ORF-2 [14].

Results and discussion

The assay was validated with serial dilutions of standards ranging from 100 to 1010 copies per reaction. The dual sets of primers used showed satisfactory amplification on four different days with assay efficiencies in the range of 81.8% - 82.9% (slopes of the standard curve −3.81 to −3.85). The assay was linear in the range of standards used (co-efficient of regression, R2) of 0.99 (Figure 1), which indicates a good correlation between viral copy numbers and cycle threshold (CT) values. The lower limit of quantification was determined as 100 copies/reaction (equivalent to 3000 copies/mL of plasma) with an accuracy of 100 ± 5% and intra and inter-day coefficient of variations below 4% (Table 1). The observed melting curve (Melting temperature™: 85.01°C ± 0.27 (mean ± SD; Figure 2) that was clearly different from the melting curve of primer-dimers (TM ranging from 71.1 – 72.9°C) as well as the purity of the TTV-specific 96 bp amplicon in the samples that contained TTV DNA (Figure 3) confirmed the high specificity of the PCR.
Figure 1

SYBR Green based standard curve from two independent 10 fold serial dilutions of plasmid standards. Standard curve was plotted in the sample plasmid on the x-axis and threshold cycle (CT) on the y-axis. The x-axis represents human TTV in 10-fold dilutions (Log copies) and the y-axis the fluorescence data used for CT determinations in ∆Rn (baseline-corrected normalized fluorescence). Assay was in linear range of Human TTV with R2 values (square of the correlation coefficient) of 0.99.

Table 1

SYBR Green real-time PCR assay for TTV using two independent standards series

Plasmid – standardsDayCTMean ± SD (n=2)*Intra-day precisionInter-day precisionIntra-day accuracyInter-day accuracy
10 × 109
1
4.11 ± 0.09
2.22
0.74
99.9
100.1
2
4.17 ± 0.08
2.03
 
99.8
 
3
4.11 ± 0.09
2.36
 
99.7
 
4
4.09 ± 0.02
0.50
 
100.2
 
10 × 108
1
7.14 ± 0.07
1.10
0.92
102
102.3
2
7.24 ± 0.22
3.10
 
101.8
 
3
7.08 ± 0.06
0.88
 
102.1
 
4
7.11 ± 0.10
1.53
 
102.3
 
10 × 107
1
11.15 ± 0.05
0.45
0.85
101.2
101.4
2
11.03 ± 0.16
1.49
 
101.6
 
3
11.26 ± 0.12
1.07
 
100.8
 
4
11.19 ± 0.06
0.58
 
101.1
 
10 × 106
1
15.21 ± 0.03
0.20
0.31
99.8
100.2
2
15.10 ± 0.02
0.15
 
100.1
 
3
15.19 ± 0.01
0.11
 
100
 
4
15.19 ± 0.003
0.02
 
99.9
 
10 × 105
1
19.15 ± 0.009
0.04
0.28
98.5
98.9
2
19.03 ± 0.06
0.35
 
98.8
 
3
19.14 ± 0.02
0.10
 
98.9
 
4
19.11 ± 0.02
0.12
 
98.6
 
10 × 104
1
22.89 ± 0.009
0.03
0.30
97.9
97.8
2
22.86 ± 0.09
0.43
 
97.5
 
3
22.98 ± 0.13
0.57
 
97.9
 
4
23.00 ± 0.05
0.25
 
96.8
 
10 × 103
1
26.95 ± 0.06
0.24
0.22
94.2
94.3
2
26.87 ± 0.04
0.17
 
93.9
 
3
26.95 ± 0.005
0.01
 
95.3
 
4
27.02 ± 0.13
0.50
 
92.9
 
10 × 102
1
30.83 ± 0.16
0.52
0.35
89.6
88.2
2
30.89 ± 0.08
0.26
 
87.2
 
3
31.08 ± 0.03
0.12
 
88.5
 
4
30.97 ± 0.13
0.42
 
86.6
 
10 × 101
1
34.29 ± 0.30
0.89
0.66
86.3
92.7
2
33.78 ± 0.57
1.70
 
93.8
 
3
33.93 ± 0.77
2.29
 
97.8
 
 433.87 ± 0.561.65 92.3 

*2 independent 10-fold dilution series (n=2) of plasmid standards.

Figure 2

Melting curve analysis of TTV real-time PCR products. Y-axis represents the derivative reporter (∆Rn) while x-axis represents the temperature (°C). The figure shows a melting temperature (Tm) of human TTV PCR products as 85.4°C with no amplifications detected in negative controls except primer-dimers.

Figure 3

Agarose gel (3%) electrophoresis of SYBR Green real-time PCR products. The gel picture shows the presence of primer-dimers in negative control (Lane 6 and Lane 7) and specific TTV amplified products (96 bp) in Lanes 2, 3, 4 and 5. Lane 1 and Lane 8 contained 50 bp DNA ladder.

SYBR Green based standard curve from two independent 10 fold serial dilutions of plasmid standards. Standard curve was plotted in the sample plasmid on the x-axis and threshold cycle (CT) on the y-axis. The x-axis represents human TTV in 10-fold dilutions (Log copies) and the y-axis the fluorescence data used for CT determinations in ∆Rn (baseline-corrected normalized fluorescence). Assay was in linear range of Human TTV with R2 values (square of the correlation coefficient) of 0.99. Melting curve analysis of TTV real-time PCR products. Y-axis represents the derivative reporter (∆Rn) while x-axis represents the temperature (°C). The figure shows a melting temperature (Tm) of human TTV PCR products as 85.4°C with no amplifications detected in negative controls except primer-dimers. Agarose gel (3%) electrophoresis of SYBR Green real-time PCR products. The gel picture shows the presence of primer-dimers in negative control (Lane 6 and Lane 7) and specific TTV amplified products (96 bp) in Lanes 2, 3, 4 and 5. Lane 1 and Lane 8 contained 50 bp DNA ladder. SYBR Green real-time PCR assay for TTV using two independent standards series *2 independent 10-fold dilution series (n=2) of plasmid standards. SYBR Green Real-time PCR quantification assay was reproducible with good inter (co-efficient of variation (CV): 0.22 to 1.23%), and intra-day (CV: 0.01 to 3.10%) precision (Table 1). The calculated standard copy numbers were accurate with intra-day and inter-day accuracies in the range of 86.3 to 102.3% and 88.2 to 102.3%, respectively (Table 1). We also observed good reproducibility of the assay when standards were run in triplicates on two different days with intra- and inter-assay precisions of 0.08 to 3.93% and 0.45 to 2.69%, respectively. The intra and inter-day accuracies were 83.8 to 102.1% and 84.3 to 101.3%, respectively (Table 2). Furthermore, our assay yielded similar TTV titers (± 10% variation) in positive controls (4.75 log copies/mL and 2.94 log copies/mL) that were kindly provided by Maggi’s group, Pisa, Italy.
Table 2

SYBR Green PCR assay for TTV using single series of plasmid standards

Plasmid standardsDayCTMean ± SD (n=3)*Intra-day precisionInter-day precisionIntra-day accuracyInter-day accuracy
10 × 109
1
4.21 ± 0.02
0.50
0.45
99.6
99.6
2
4.18 ± 0.01
0.39
 
99.6
 
10 × 108
1
7.59 ± 0.05
0.75
0.65
101.3
101.3
2
7.52 ± 0.05
0.78
 
101.2
 
10 × 107
1
11.74 ± 0.05
0.45
1.10
100.8
100.8
2
11.56 ± 0.01
0.14
 
100.8
 
10 × 106
1
15.83 ± 0.04
0.28
1.22
100.4
100.4
2
15.56 ± 0.01
0.08
 
100.4
 
10 × 105
1
19.75 ± 0.05
0.26
1.39
100.6
100.7
2
19.37 ± 0.01
0.10
 
100.8
 
10 × 104
1
24.15 ± 0.03
0.12
1.52
98.1
98.4
2
23.64 ± 0.02
0.10
 
98.6
 
10 × 103
1
28.40 ± 0.03
0.12
1.64
95.3
95.8
2
27.75 ± 0.05
0.19
 
96.4
 
10 × 102
1
33.21 ± 0.20
0.62
1.51
83.8
84.3
2
32.51 ± 0.06
0.21
 
84.8
 
10 × 101
1
35.59 ± 0.39
1.11
0.67
102.1
99.0
 235.25 ± 0.060.17 95.7 

*Tenfold dilutions run in triplicates.

SYBR Green PCR assay for TTV using single series of plasmid standards *Tenfold dilutions run in triplicates. In order to check the robustness of the SYBR Green qPCR assay, we measured TTV titers in plasma samples of 20 healthy individuals and 30 HSCT recipients. Variations in TTV loads in terms of log copy numbers of TTV genomes per mL of plasma were found to be in the range of 2.5 – 4.07 log copies/mL (Figure 4A) with a CT (mean ± SD) of 33.8 ± 1.77 for healthy individuals and 2.06 – 8.49 log copies/mL (Figure 4A) with a CT (mean ± SD) of 24.3 ± 1.04 for HSCT recipients. In addition, we observed the differences in melting curves for HSCT recipients (TM ranging from 82.61°C-84.85°C; Figure 4B) which might be due to possible sequence heterogeneity of human TTV strains, with the presence of TTV specific products (96 bp) on 3% agarose gel electrophoresis (Figure 4C).
Figure 4

TTV DNA in healthy individuals (n=20) and in HSCT recipients (n=30) by SYBR Green assay.A represents the log copies per mL of plasma for each healthy individual and HSCT recipient tested. B shows the melting curves for HSCT recipients and C shows 3% agarose gel picture with 50 bp DNA ladder in Lane 1, Lane 2 contained positive control (plasmid vector containing TTV insert), Lane 3 - Lane 15 shows the presence of TTV specific PCR products (96 bp) from HSCT recipients while Lane 16 contains the negative control.

TTV DNA in healthy individuals (n=20) and in HSCT recipients (n=30) by SYBR Green assay.A represents the log copies per mL of plasma for each healthy individual and HSCT recipient tested. B shows the melting curves for HSCT recipients and C shows 3% agarose gel picture with 50 bp DNA ladder in Lane 1, Lane 2 contained positive control (plasmid vector containing TTV insert), Lane 3 - Lane 15 shows the presence of TTV specific PCR products (96 bp) from HSCT recipients while Lane 16 contains the negative control. Several TTV studies using TaqMan chemistry have reported varying levels of sensitivity, ranging from 120 to 1000 copies/mL for different types of clinical specimens [5,14,15,17-22], which may be the result of differences in the primers used. Although sequence heterogeneity in TTV is high with some variants only sharing 50% of nucleotides [23,24], certain conserved regions can be chosen for primer design in order to amplify more than one subtype of TTV [25]. Focosi et al. [5] and Maggi et al. [19] used probes directed against the conserved portion of untranslated region (UTR), while others used probes specific for highly conserved region of ORF2 and ORF1 of TTV [14,15,17]. For our qPCR protocol we used the primers described by Moen et al.[14] that differentiate between TTV and TTV-like mini virus (TLMV). Although TaqMan based assays may be somewhat more sensitive, we opted for SYBR Green assay using a primer pair rather than TaqMan technology, which uses two primers and one probe, and is probably more prone to the problem of variable amplification efficacy of strains differing for single nucleotides. Indeed, in our sequencing results for 12 separate clones (Figure 5) from one single patient we observed sequence heterogeneity of TTV in the region that has been used for TaqMan probe [14]. In general, SYBR Green methodology may be more suitable for viral studies where sequence heterogeneity is high in comparison to TaqMan probe-based assays which require high sequence identity for successful probe binding to avoid frequent variable results [14]. In addition, the assay’s threshold of 3000 copies/mL of plasma may be low enough for monitoring TTV in immune deficient patients.
Figure 5

Sequence alignments of 12 separate TTV clones from a single patient with TTV sequence (AB008394). The figure shows forward and reverse primers location highlighted in green along with base changes highlighted in blue that were used in dual set of primers for SYBR Green assay and other base changes detected in primer region are highlighted in red. Probe region used previously for TaqMan [14] highlighted in brown.

Sequence alignments of 12 separate TTV clones from a single patient with TTV sequence (AB008394). The figure shows forward and reverse primers location highlighted in green along with base changes highlighted in blue that were used in dual set of primers for SYBR Green assay and other base changes detected in primer region are highlighted in red. Probe region used previously for TaqMan [14] highlighted in brown.

Conclusion

This report describes the validation of a SYBR Green assay for quantification of TTV viral load in human plasma samples. The developed assay was accurate with satisfactory efficiency, reproducibility in the range of 100-1010 copies/ reaction. This simple assay can be used in studies assessing TTV plasma loads as a marker of immune reconstitution. A prospective study is currently ongoing in our institution to validate the correlation of TTV titer and the immune status post HSCT.

Methods

Reagents and consumables

QIAamp® MinElute virus spin kit for DNA extraction, QIAprep® Spin Miniprep kit for plasmid extraction and QIAquick® PCR purification kit were obtained from Qiagen, Germany. TA cloning kit dual promoter (pCRII) with One Shot TOP10F`competent cells and ampicillin were obtained from Invitrogen, San Diego, California. DNA Taq polymerase, BamHI and EcoRI restriction enzymes were obtained from New England BioLabs, USA. SYBR®-Green PCR master mix, 96 well MicroAmp® fast optical reaction plates (0.1 mL capacity) and MicroAmp® optical adhesive films for real-time PCR assay were obtained from Applied Biosystems, Fostercity, CA. All the experiments were performed on StepOnePlus®-Real Time PCR Systems by Applied Biosystems, Fostercity, CA. For amplification of human torque teno virus (TTV), a set of primer pairs described previously were used (Table 3). Primers were made according to the reference strain of TTV genome TA 278 (Gen Bank acc. No. AB008394) and were synthesized by Microsynth (Switzerland) at a scale of 0.2 μmol. DNA ladders, MgCl2, dNTP’s and buffers were obtained from Fermentas Life sciences, Germany.
Table 3

Oligonucleotide primers used for human torque teno virus (TTV)

Primers IDSequence (5` to 3`)Nucleotide position*Reference
TTVf
TCCGAATGGCTGAGTTT
102-118
Moen EM et al.[19]
TTVr
CGAATTGCCCCTTGACT
219-203
 
TTV-F1
GTTTTCTACGCCCGTCC
115-131
 
TTV-F2
GTTTTCCACGCCCGTCC
115-131
 
TTV-R1
CCTTGACTCCGGTGTGTAA
210-192
 
TTV-R2CCTTGACTTCGGTGTGTAA210-192 

*According to the reference strain of TTV genome TA 278 (Gen Bank acc. No. AB008394).

Oligonucleotide primers used for human torque teno virus (TTV) *According to the reference strain of TTV genome TA 278 (Gen Bank acc. No. AB008394).

Samples and DNA extraction

Blood samples (5 mL) collected in EDTA tubes from 20 healthy adult volunteers and 30 randomly selected adult HSCT recipients were centrifuged at 900 g for 10 minutes to separate plasma which was immediately frozen at -20°C until used for DNA extraction. Two independent DNA extractions were performed for each of the healthy individuals along with one independent DNA extraction for HSCT recipients, each from 200 μl of plasma using QIAamp MinElute Virus Spin kit according to the manufacturer’s recommendations. DNA was eluted in 30 μL of Milli-Q water. All extracted DNA samples were stored at -20°C until the analysis. The study protocol was approved by the institution’s ethics committee and healthy donors and HSCT recipient’s samples were used after obtaining informed consent.

Construction of plasmids for standards preparation

A region of 119 bp PCR fragment of TTV genome was amplified using primers TTVf and TTVr (Table 3). Resulting amplicon was purified using QIAquick PCR Purification kit, quantified by spectrophotometer and then cloned into the TA cloning vector. The resulting plasmid was transformed into One Shot TOP10F` competent cells according to instructions provided by the manufacturer. Twelve, isolated colonies of transformed competent cells from solid luria-bertani medium containing ampicillin (100 μg/mL) were subjected for TTV insert confirmation. Each individual colony was suspended separately into 3 mL of liquid luria-bertani medium containing 100 μg/mL of ampicillin for overnight in a shaking incubator at 37°C with a speed of 225 rpm. Following overnight incubation, plasmids purification was done using QIA prep Spin Miniprep kit according to manufacturer’s instructions. Restriction enzyme digestion with EcoRI for the purified plasmids was done to confirm the presence of cloned TTV insert (119 bp) on 1.5% agarose gel electrophoresis (data not shown). TTV insert (119 bp) cloned into TA vector were sequenced for all the 12 separate clones using M-13 forward and reverse primers and confirmed by aligning with the TTV sequence (Gen Bank acc. no. AB008394). This plasmid with TTV inserts was linearized with BamHI enzyme and then used for preparation of standards in serial 10 fold dilutions from 10×109 copies to 20 copies/μL.

Absolute quantification of TTV DNA

PCR reaction for absolute quantification of TTV DNA using SYBR Green in a 25 μL reaction is as follows: each reaction contained 12.5 μL SYBR Green PCR master mix, 5 μL of template (serial 10 fold dilutions of the linearized plasmid standards or/ extracted DNA from the plasma samples of healthy blood donors), 1.25 μL (500 nm) of each primer (TTVF-1, TTVF-2, TTVR-1, TTVR-2) and 2.5 μL of Milli-Q water. The cycling conditions included initial activation of AmpliTaq Gold DNA polymerase (present in SYBR Green master mix) for 10 minutes at 95°C. The subsequent PCR conditions consisted of 40 cycles of denaturation at 95°C for 15 seconds and annealing and extension at 60°C for 1 minute per cycle. After real-time data acquisition, the cycle threshold value was calculated by determining the point at which the fluorescence exceeds an arbitrary threshold limit. Standards with known TTV DNA copies were prepared in two independent serial dilutions and were run in the range of 100 copies to 10×109 copies on four non-consecutive days to evaluate biological, inter, intraday variability and accuracy of the assay. In addition, a series of standards from one serial dilution were also run in triplicates on two different days to evaluate the intra-day and inter-day variations. The variability of the assay was evaluated by comparing the CT values run on the same day (intra-day) and on different days (inter-day) and was represented as co-efficient of variations (CV). Accuracy was calculated by taking the ratio of back calculated copies from the standard curve to the theoretical copy number of the reactions. Real-time PCR assay for test samples (HSCT recipients) and for biological replicates of each healthy individual were performed with the inclusion of TTV plasmid standards and negative controls in each run. In addition to this, precision of the assay was also checked by running known TTV positive DNA (positive controls with exact log copies/mL). The viral genomic copies per mL of plasma was calculated as described by Huang et al. [26] i.e., by multiplying the copies per reaction by a factor of 30 [30 μL extracted DNA/5 μL of template x (1 mL/200 μL plasma)].

Melting curve analysis for specificity

Following amplification, melting curve or dissociation curve analysis was performed to measure the specificity of the PCR product. The temperature program used for the melting curve analysis was 95°C for 15 seconds followed by 60°C for 1 minute and then 95°C for 15 seconds with ramp rate of +0.3°C/second.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

AKT and AP performed the experiments. AKT, AP, PHD, CRSU and MA analyzed and contributed to the interpretation of data. MA and ER designed the research. AKT and MA drafted the article. All the authors revised the manuscript critically. All authors read and approved the final manuscript.
  24 in total

1.  Genomic and molecular evolutionary analysis of a newly identified infectious agent (SEN virus) and its relationship to the TT virus family.

Authors:  Y Tanaka; D Primi; R Y Wang; T Umemura; A E Yeo; M Mizokami; H J Alter; J W Shih
Journal:  J Infect Dis       Date:  2000-12-20       Impact factor: 5.226

2.  Development of a TT virus DNA quantification system using real-time detection PCR.

Authors:  T Kato; M Mizokami; M Mukaide; E Orito; T Ohno; T Nakano; Y Tanaka; H Kato; F Sugauchi; R Ueda; N Hirashima; K Shimamatsu; M Kage; M Kojiro
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

3.  TT virus infection: prevalence of elevated viraemia and arguments for the immune control of viral load.

Authors:  M Touinssi; P Gallian; P Biagini; H Attoui; B Vialettes; Y Berland; C Tamalet; C Dhiver; I Ravaux; P De Micco; X De Lamballerie
Journal:  J Clin Virol       Date:  2001-05       Impact factor: 3.168

4.  Characterization of a highly divergent TT virus genome.

Authors:  R L Hallett; J P Clewley; F Bobet; P J McKiernan; C G Teo
Journal:  J Gen Virol       Date:  2000-09       Impact factor: 3.891

5.  Full or near full length nucleotide sequences of TT virus variants (Types SANBAN and YONBAN) and the TT virus-like mini virus.

Authors:  K Takahashi; M Hijikata; E I Samokhvalov; S Mishiro
Journal:  Intervirology       Date:  2000       Impact factor: 1.763

Review 6.  Molecular properties, biology, and clinical implications of TT virus, a recently identified widespread infectious agent of humans.

Authors:  M Bendinelli; M Pistello; F Maggi; C Fornai; G Freer; M L Vatteroni
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

7.  Identification of a new human DNA virus (TTV-like mini virus, TLMV) intermediately related to TT virus and chicken anemia virus.

Authors:  K Takahashi; Y Iwasa; M Hijikata; S Mishiro
Journal:  Arch Virol       Date:  2000       Impact factor: 2.574

8.  Low prevalence of TT virus in the cerebrospinal fluid of viremic patients with central nervous system disorders.

Authors:  F Maggi; C Fornai; M L Vatteroni; G Siciliano; F Menichetti; C Tascini; S Specter; M Pistello; M Bendinelli
Journal:  J Med Virol       Date:  2001-10       Impact factor: 2.327

9.  Torque teno virus in fecal samples of patients with gastroenteritis: prevalence, genogroups distribution, and viral load.

Authors:  Carlos Augusto Pinho-Nascimento; José Paulo Gagliardi Leite; Christian Niel; Leonardo Diniz-Mendes
Journal:  J Med Virol       Date:  2011-06       Impact factor: 2.327

10.  TT virus levels in the plasma of infected individuals with different hepatic and extrahepatic pathology.

Authors:  M Pistello; A Morrica; F Maggi; M L Vatteroni; G Freer; C Fornai; F Casula; S Marchi; P Ciccorossi; P Rovero; M Bendinelli
Journal:  J Med Virol       Date:  2001-02       Impact factor: 2.327

View more
  9 in total

1.  TTV DNA plasma load and its association with age, gender, and HCMV IgG serostatus in healthy adults.

Authors:  Mats Haloschan; Rainer Bettesch; Irene Görzer; Lukas Weseslindtner; Michael Kundi; Elisabeth Puchhammer-Stöckl
Journal:  Age (Dordr)       Date:  2014-10-05

2.  Torque Teno Virus plasma level as novel biomarker of retained immunocompetence in HIV-infected patients.

Authors:  A Fuchs; N Lübke; L Schmidt; B-E O Jensen; A Walker; V Keitel-Anselmino; V di Cristanziano; M Böhm; E Knops; E Heger; R Kaiser; A de Luca; M Oette; D Häussinger; J Timm
Journal:  Infection       Date:  2021-02-03       Impact factor: 3.553

3.  Pre-transplant plasma Torque Teno virus load and increase dynamics after lung transplantation.

Authors:  Irene Görzer; Peter Jaksch; Michael Kundi; Tamara Seitz; Walter Klepetko; Elisabeth Puchhammer-Stöckl
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

4.  Composite Analysis of the Virome and Bacteriome of HIV/HPV Co-Infected Women Reveals Proxies for Immunodeficiency.

Authors:  Juliana D Siqueira; Gislaine Curty; Deng Xutao; Cristina B Hofer; Elizabeth S Machado; Héctor N Seuánez; Marcelo A Soares; Eric Delwart; Esmeralda A Soares
Journal:  Viruses       Date:  2019-05-07       Impact factor: 5.048

5.  Torque Teno Virus Viral Load as a Marker of Immune Function in Allogeneic Haematopoietic Stem Cell Transplantation Recipients.

Authors:  William Mouton; Anne Conrad; Antonin Bal; Mathilde Boccard; Christophe Malcus; Sophie Ducastelle-Lepretre; Marie Balsat; Fiorenza Barraco; Marie-Virginie Larcher; Gaëlle Fossard; Hélène Labussière-Wallet; Florence Ader; Karen Brengel-Pesce; Sophie Trouillet-Assant; Lyon Heminf Study Group
Journal:  Viruses       Date:  2020-11-11       Impact factor: 5.048

6.  Circulating virome and inflammatory proteome in patients with ST-elevation myocardial infarction and primary ventricular fibrillation.

Authors:  Teresa Oliveras; Elena Revuelta-López; Cosme García-García; Adriana Cserkóová; Ferran Rueda; Carlos Labata; Marc Ferrer; Santiago Montero; Nabil El-Ouaddi; Maria José Martínez; Santiago Roura; Carolina Gálvez-Montón; Antoni Bayes-Genis
Journal:  Sci Rep       Date:  2022-05-12       Impact factor: 4.996

7.  Identification of heterologous Torque Teno Viruses in humans and swine.

Authors:  Marvin A Ssemadaali; Karl Effertz; Pankaj Singh; Oleksandr Kolyvushko; Sheela Ramamoorthy
Journal:  Sci Rep       Date:  2016-05-25       Impact factor: 4.379

Review 8.  Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders.

Authors:  Giovanni Di Minno; Carlo Federico Perno; Andreas Tiede; David Navarro; Mariana Canaro; Lutz Güertler; James W Ironside
Journal:  Blood Rev       Date:  2015-07-20       Impact factor: 8.250

9.  Torque Teno Virus as a Potential Biomarker for Complications and Survival After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Amandine Pradier; Stavroula Masouridi-Levrat; Carine Bosshard; Carole Dantin; Diem-Lan Vu; Marie-Céline Zanella; Elsa Boely; Caroline Tapparel; Laurent Kaiser; Yves Chalandon; Federico Simonetta; Eddy Roosnek
Journal:  Front Immunol       Date:  2020-05-27       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.